1
|
Figueiredo JC, Ihenacho U, Merin NM, Hamid O, Darrah J, Gong J, Paquette R, Mita AC, Vescio R, Mehmi I, Basho R, Salvy SJ, Shirazipour CH, Caceres N, Finster LJ, Coleman B, Arnow HU, Florindez L, Sobhani K, Prostko JC, Frias EC, Stewart JL, Merchant A, Reckamp KL. SARS-CoV-2 vaccine uptake, perspectives, and adverse reactions following vaccination in patients with cancer undergoing treatment. Ann Oncol 2022; 33:109-111. [PMID: 34687893 PMCID: PMC8527840 DOI: 10.1016/j.annonc.2021.10.004] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2021] [Revised: 10/02/2021] [Accepted: 10/13/2021] [Indexed: 11/25/2022] Open
Affiliation(s)
- J C Figueiredo
- Division of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, USA.
| | - U Ihenacho
- Division of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, USA; Keck School of Medicine, University of Southern California, Los Angeles, USA
| | - N M Merin
- Division of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, USA
| | - O Hamid
- The Angeles Clinic and Research Institute, Cedars-Sinai Medical Center, Los Angeles, USA
| | - J Darrah
- Division of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, USA
| | - J Gong
- Division of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, USA
| | - R Paquette
- Division of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, USA
| | - A C Mita
- Division of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, USA
| | - R Vescio
- Division of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, USA
| | - I Mehmi
- Division of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, USA
| | - R Basho
- Division of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, USA
| | - S J Salvy
- Division of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, USA
| | - C H Shirazipour
- Division of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, USA; Department of Medicine, University of California Los Angeles, Los Angeles, USA
| | - N Caceres
- Division of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, USA
| | - L J Finster
- Division of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, USA
| | - B Coleman
- Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, USA
| | - H U Arnow
- Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, USA
| | - L Florindez
- Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, USA
| | - K Sobhani
- Division of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, USA
| | | | - E C Frias
- Abbott Diagnostics, Abbott Park, USA
| | | | - A Merchant
- Division of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, USA
| | - K L Reckamp
- Division of Medical Oncology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, USA.
| |
Collapse
|
2
|
Krug LM, Wozniak AJ, Kindler HL, Feld R, Koczywas M, Morero JL, Rodriguez CP, Ross HJ, Bauman JE, Orlov SV, Ruckdeschel JC, Mita AC, Fein L, He X, Hall R, Kawabe T, Sharma S. Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma. Lung Cancer 2014; 85:429-34. [PMID: 25047675 DOI: 10.1016/j.lungcan.2014.06.008] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2014] [Revised: 06/10/2014] [Accepted: 06/13/2014] [Indexed: 10/25/2022]
Abstract
BACKGROUND CBP501, a synthetic duodecapeptide, increases cisplatin influx into tumor cells through an interaction with calmodulin enhancing cisplatin cytotoxicity, and effects cell cycle progression by abrogating DNA repair at the G2 checkpoint. In phase I clinical trials of CBP501 alone or in combination with cisplatin, the most common toxicity was infusion-related urticaria. Activity of CBP501 plus cisplatin was observed in patients with ovarian cancer and mesothelioma, including some patients previously treated with cisplatin. METHODS Chemotherapy naïve patients with unresectable MPM were stratified by histology and performance status, and randomized 2:1 to pemetrexed/cisplatin plus CBP501 25mg/m(2) IV (Arm A) or pemetrexed/cisplatin alone (Arm B). The primary endpoint was progression free survival (PFS) at 4 months. RESULTS 65 patients were randomized, and 63 were treated. Patient characteristics in the two arms were balanced. Based on independent radiology review of the treated population, 25/40 patients (63%) in Arm A and 9/23 (39%) in Arm B had PFS≥4mo; the median PFS was 5.1mo (95% CI, 3.9, 6.5) vs 3.4mo (2.5, 6.7). Median OS was 13.3mo (9.2, 16.3) in Arm A and 12.8 (6.5, 16.1) in Arm B. Adverse events were not different than expected from standard chemotherapy, and comparable in the two arms, aside from infusion reactions which occurred in 70% of patients treated with CBP501. CONCLUSIONS While this randomized phase II trial met its primary endpoint of PFS at 4 months, other parameters such as response rate and overall survival suggest that the addition of CBP501 does not improve the efficacy of standard chemotherapy for MPM.
Collapse
Affiliation(s)
- L M Krug
- Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA.
| | | | | | - R Feld
- Princess Margaret Hospital, Toronto, ON, Canada
| | - M Koczywas
- City of Hope Cancer Center, Duarte, CA, USA
| | - J L Morero
- Hospital Maria Ferrer, Buenos Aires, Argentina
| | | | - H J Ross
- Mayo Clinic Arizona, Scottsdale, AZ, USA
| | - J E Bauman
- University of New Mexico, Albuquerque, NM, USA
| | - S V Orlov
- St. Petersburg Medical University, St. Petersburg, Russia
| | | | - A C Mita
- Cedars-Sinai Medical Center, Los Angeles, CA, USA
| | - L Fein
- Centro Oncologico de Rosario, Rosario, Argentina
| | - X He
- ICON Clinical Research, North Wales, PA, USA
| | - R Hall
- ICON Clinical Research, North Wales, PA, USA
| | - T Kawabe
- CanBas Co., Ltd., Numazu City, Shizuoka, Japan
| | - S Sharma
- Huntsman Cancer Institute, Salt Lake City, UT, USA
| |
Collapse
|
3
|
Snyder LA, Honea N, Coons SW, Eschbacher J, Smith KA, Spetzler RF, Sanai N, Groves MD, DeGroot J, Tremont I, Forman A, Kang S, Pei BL, Julie W, Schultz D, Yuan Y, Guha N, Hwu WJ, Papadopoulos N, Camphausen K, Yung WA, Ryken T, Johnston SK, Graham C, Grimm S, Colman H, Raizer J, Chamberlain MC, Mrugala MM, Adair JE, Beard BC, Silbergeld DL, Rockhill JK, Kiem HP, Lee EQ, Batchelor TT, Lassman AB, Schiff DS, Kaley TJ, Wong ET, Mikkelsen T, Purow BW, Drappatz J, Norden AD, Beroukhim R, Weiss S, Alexander BM, Sceppa C, Gerard M, Hallisey SD, Bochacki CA, Smith KH, Muzikansky AM, Wen PY, Peereboom DM, Mikkelson T, Sloan AE, Rich JN, Supko JG, Ye X, Brewer C, Lamborn K, Prados M, Grossman SA, Zhu JJ, Recht LD, Colman H, Kesari S, Kim LJ, Balch AH, Pope CC, Brulotte M, Beelen AP, Chamberlain MC, Wong ET, Ram Z, Gutin PH, Stupp R, Marsh J, McDonald K, Wheeler H, Teo C, Martin L, Palmer L, Rodriguez M, Buckland M, Koh ES, Back M, Robinson B, Joseph D, Nowak AK, Saito R, Sonoda Y, Yamashita Y, Kanamori M, Kumabe T, Tominaga T, Rodon J, Tawbi HA, Thomas AL, Amakye DD, Granvil C, Shou Y, Dey J, Buonamici S, Dienstmann R, Mita AC, Dummer R, Hutterer M, Martha N, Sabine E, Thaddaus G, Florian S, Christine M, Stefan O, Richard G, Martin M, Johanna B, Jochen T, Ullrich H, Wolfgang W, Peter V, Gunther S, Field KM, Cher L, Wheeler H, Hovey E, Nowak AK, Simes J, Sawkins K, France T, Brown C, Nicholas MK, Chmura S, Paleologos N, Krouwer H, Malkin M, Junck L, Vick NA, Lukas RV, Jaeckle KA, Anderson SK, Kosel M, Sarkaria J, Brown P, Flynn PJ, Buckner JC, Galanis E, Batchelor T, Grossman S, Brem S, Lesser G, Voloschin A, Nabors LB, Mikkelsen T, Desideri S, Supko J, Peereboom D, Westphal M, Pietsch T, Bach F, Heese O, Vredenburgh JJ, Desjardins A, Reardon DA, Peters KB, Kirkpatrick JP, Herndon JE, Coan AD, Bailey L, Janney D, Lu C, Friedman HS, Desjardins A, Reardon DA, Peters KB, Herndon JE, Gururangan S, Norfleet J, Friedman HS, Vredenburgh JJ, Lassman AB, Kaley TJ, DeAngelis LM, Hormigo A, Mellinghoff IK, Otap DD, Seger J, Doyle LA, Ludwig E, Lacouture ME, Panageas KS, Rezazadeh A, LaRocca RV, Vitaz TW, Villanueva WG, Hodes J, Haysley L, Pertschuk D, Cloughesy TF, Chang SM, Aghi MK, Vogelbaum MA, Liau LM, Shafa B, Jolly DJ, Ibanez CE, Perez OD, Robbins JM, Gruber HE, Maher EA, Stewart C, Hatanpaa K, Raisanen J, Mashimo T, Yang XL, Muralidhara C, Madden C, Ramachandran A, Mickey B, Bachoo R. ONGOING CLINICAL TRIALS. Neuro Oncol 2011; 13:iii85-iii91. [PMCID: PMC3199166 DOI: 10.1093/neuonc/nor154] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2023] Open
|
4
|
Mita AC, Papadopoulos K, de Jonge MJA, Schwartz G, Verweij J, Mita MM, Ricart A, Chu QSC, Tolcher AW, Wood L, McCarthy S, Hamilton M, Iwata K, Wacker B, Witt K, Rowinsky EK. Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer. Br J Cancer 2011; 105:938-44. [PMID: 21878940 PMCID: PMC3185947 DOI: 10.1038/bjc.2011.332] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Revised: 07/22/2011] [Accepted: 08/01/2011] [Indexed: 11/08/2022] Open
Abstract
BACKGROUND To evaluate the anticancer activity of erlotinib in patients with previously treated, advanced non-small cell lung cancer (NSCLC) whose dose is increased to that associated with a maximal level of tolerable skin toxicity (i.e., target rash (TR)); to characterise the pharmacokinetics (PK) and pharmacodynamics (PD) of higher doses of erlotinib. METHODS Patients initially received erlotinib 150 mg per day. The dose was successively increased in each patient to that associated with a TR. Anticancer activity was evaluated. Plasma, skin, and hair were sampled for PK and PD studies. RESULTS Erlotinib dose escalation to 200-475 mg per day was feasible in 38 (90%) of 42 patients. Twenty-four (57%) patients developed a TR, but 19 (79%) did so at 150 mg per day. Five (12%) patients, all of whom developed a TR, had a partial response. Median progression-free survival (PFS) was 2.3 months (95% CI: 1.61, 4.14); median PFS was 3.5 months and 1.9 months, respectively, for patients who did and did not experience a TR (hazard ratio, 0.51; P=0.051). Neither rash severity nor response correlated with erlotinib exposure. CONCLUSION Intrapatient dose escalation of erlotinib does not appreciably increase the propensity to experience a maximal level of tolerable skin toxicity, or appear to increase the anticancer activity of erlotinib in NSCLC.
Collapse
Affiliation(s)
- A C Mita
- Institute for Drug Development, Cancer Therapy and Research Center, University of Texas Health Science Center, 4th Floor, 7979 Wurzbach Road, Zeller Building, San Antonio, TX 78229, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Mita AC, Mita MM, Rocha C, Bradley CR, Sarantopoulos J, O'Rourke P, Gadgeel SM, Wozniak AJ, Heath EI. A phase IB trial of iniparib (BSI-201) in combination with carboplatin (C)/paclitaxel (P) in patients with non-small cell lung cancer (NSCLC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.7570] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
6
|
Sankhala KK, Tolcher AW, Mita MM, Gordon MS, Rosen LS, Papadopoulos KP, Patnaik A, Drengler RL, Mita AC, Sarantopoulos J, Bristow RG, Fine G, Choy GS, Azab M. Amuvatinib (MP-470), an oral dual inhibitor of mutant kinases and DNA repair: Final results from a 100-patient, 5-arm phase Ib trial in combination with five standard of care (SOC) anticancer regimens. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3074] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
7
|
Mita MM, Mita AC, Moseley J, Poon J, Small KA, Jou Y, Kirschmeier P, Zhang D, Statkevich P, Sankhala KK, Sarantopoulos J, Cleary JM, Chirieac LR, Rodig S, Bannerji R, Shapiro G. A phase I study of the CDK inhibitor dinaciclib (SCH 727965) administered every 3 weeks in patients (pts) with advanced malignancies: Final results. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3080] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
8
|
Vemulapalli S, Mita AC, Gallegos NS, Anderson G, Charles J, Rogers JM, Kousba A, Sankhala KK, Nemunaitis JJ. Phase I study of ATI-1123, a novel human serum albumin-stabilized docetaxel liposomal formulation, in patients with advanced solid malignancies. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.2609] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
9
|
Mahalingam D, Sarantopoulos J, Gordon MS, Pandya NB, Tan BR, Mita AC, Zergebel C, Saito K, Takimoto CH, Saif MW. Phase I study evaluating the pharmacokinetics (PK) of components of S-1 in patients with impaired hepatic function. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.2612] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
10
|
Daniels GA, Carson WE, Mita AC, Kendra KL, Rahimy MH, Inman DW, Appleman JR, Freddo JL, McNeel DG. Phase I open-label, dose-escalation study of ANA773 tosylate, an oral prodrug of a toll-like receptor-7 agonist, in patients with advanced solid tumors. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.2524] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
11
|
Chen N, Chawla SP, Chiorean EG, Read WL, Gorbaty M, Mita AC, Yung L, McNally R, Renschler MF, Sharma S. Phase I study to assess pharmacokinetics (PK), QT/QTc effect, and safety of amrubicin in patients (pts) with advanced solid tumors. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.7073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
12
|
Tawbi HA, Rodon Ahnert J, Dummer R, Thomas AL, Granvil C, Shou Y, Dey J, Mita MM, Amakye DD, Mita AC. Phase I study of LDE225 in advanced solid tumors: Updated analysis of safety, preliminary efficacy, and pharmacokinetic-pharmacodynamic correlation. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.3062] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
13
|
Borad MJ, Chiorean EG, Molina JR, Mita AC, Infante JR, Schelman WR, Traynor AM, Vlahovic G, Mendelson DS, Reddy SG. Clinical benefits TH-302, a tumor-selective, hypoxia-activated prodrug, and gemcitabine in first-line pancreatic cancer (PanC). J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.4_suppl.265] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
265 Background: Gemcitabine (G) is the standard treatment for first- line PanC. PanC is one of the most hypoxic solid tumors. TH-302 is an inert prodrug of brominated isophosphoramide mustard and undergoes selective activation in deep hypoxia. As a single agent, tumor responses were reported in patients (pts) with metastatic melanoma, SCLC, and head/neck cancer at TH-302 weekly doses of 480-575 mg/m2. Methods: Eligible pts for the PanC expansion of this phase I/II study ( NCT00743379 ) had ECOG <1, locally advanced or metastatic PanC previously untreated with systemic chemotherapy other than adjuvant G, 5FU, and/or radiation. IV TH-302 was dosed at 240-575 mg/m2 (240 or 340 in expansion) with standard dose G (1000 mg/m2) on days 1, 8 and 15 of a 28-day cycle. Serum protein and microRNA hypoxia biomarkers were analyzed at baseline, start of cycle 3 and end of study. Results: 46 PanC subjects (12 locally advanced, 34 distant mets); median age: 63 (range 41-83); 24 male; ECOG 0/1 in 29/17 pts; RECIST response rate (RR) of 21%, median PFS of 6.1 mo (95%CI 4.8, 7.7) and median survival of 11.4 mo (95%CI 6.0, not reached) were observed. RR was 23% with median survival of 7.4 mo in pts with distant mets. 52% of pts had a >50% decrease in CA19-9. Common adverse events were skin or mucosal toxicity, nausea, fatigue and vomiting; most grade 1/2. Grade 3/4 neutropenia, thrombocytopenia and anemia in 68%, 64%, and 20% of pts respectively. The dose intensities at 240 mg/m2 and 340 mg/m2 were similar and related to hematologic toxicities. Skin toxicities were less common at 240 mg/m2. A TH-302 dose response was present with higher RR and PFS at 340 mg/m2. Initial serum hypoxia biomarkers did not identify a preferential pt population. Conclusions: The activity and clinical benefits of the combination of TH-302 with G in first line PanC are promising as compared to previous studies of G alone. TH-302 adds to the hematologic toxicity of G, but the regimen is well tolerated. The safety and activity provided rationale for comparing TH-302 plus G versus G alone in a randomized phase II trial ( NCT01144455 ) and indicate TH-302 may complement G by penetrating into the hypoxic regions of the PanC tumors where activation induces cytotoxicity. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- M. J. Borad
- Mayo Clinic Arizona, Scottsdale, AZ; Indiana University Simon Cancer Center, Indianapolis, IN; Mayo Clinic, Rochester, MN; Institute for Drug Development, Cancer Therapy and Research Center, The University of Texas Health Science Center at San Antonio, San Antonio, TX; Sarah Cannon Research Institute, Nashville, TN; University of Wisconsin Carbone Cancer Center, Madison, WI; Duke University Medical Center, Durham, NC; Pinnacle Oncology Hematology, Scottsdale, AZ; Louisiana State University Health
| | - E. G. Chiorean
- Mayo Clinic Arizona, Scottsdale, AZ; Indiana University Simon Cancer Center, Indianapolis, IN; Mayo Clinic, Rochester, MN; Institute for Drug Development, Cancer Therapy and Research Center, The University of Texas Health Science Center at San Antonio, San Antonio, TX; Sarah Cannon Research Institute, Nashville, TN; University of Wisconsin Carbone Cancer Center, Madison, WI; Duke University Medical Center, Durham, NC; Pinnacle Oncology Hematology, Scottsdale, AZ; Louisiana State University Health
| | - J. R. Molina
- Mayo Clinic Arizona, Scottsdale, AZ; Indiana University Simon Cancer Center, Indianapolis, IN; Mayo Clinic, Rochester, MN; Institute for Drug Development, Cancer Therapy and Research Center, The University of Texas Health Science Center at San Antonio, San Antonio, TX; Sarah Cannon Research Institute, Nashville, TN; University of Wisconsin Carbone Cancer Center, Madison, WI; Duke University Medical Center, Durham, NC; Pinnacle Oncology Hematology, Scottsdale, AZ; Louisiana State University Health
| | - A. C. Mita
- Mayo Clinic Arizona, Scottsdale, AZ; Indiana University Simon Cancer Center, Indianapolis, IN; Mayo Clinic, Rochester, MN; Institute for Drug Development, Cancer Therapy and Research Center, The University of Texas Health Science Center at San Antonio, San Antonio, TX; Sarah Cannon Research Institute, Nashville, TN; University of Wisconsin Carbone Cancer Center, Madison, WI; Duke University Medical Center, Durham, NC; Pinnacle Oncology Hematology, Scottsdale, AZ; Louisiana State University Health
| | - J. R. Infante
- Mayo Clinic Arizona, Scottsdale, AZ; Indiana University Simon Cancer Center, Indianapolis, IN; Mayo Clinic, Rochester, MN; Institute for Drug Development, Cancer Therapy and Research Center, The University of Texas Health Science Center at San Antonio, San Antonio, TX; Sarah Cannon Research Institute, Nashville, TN; University of Wisconsin Carbone Cancer Center, Madison, WI; Duke University Medical Center, Durham, NC; Pinnacle Oncology Hematology, Scottsdale, AZ; Louisiana State University Health
| | - W. R. Schelman
- Mayo Clinic Arizona, Scottsdale, AZ; Indiana University Simon Cancer Center, Indianapolis, IN; Mayo Clinic, Rochester, MN; Institute for Drug Development, Cancer Therapy and Research Center, The University of Texas Health Science Center at San Antonio, San Antonio, TX; Sarah Cannon Research Institute, Nashville, TN; University of Wisconsin Carbone Cancer Center, Madison, WI; Duke University Medical Center, Durham, NC; Pinnacle Oncology Hematology, Scottsdale, AZ; Louisiana State University Health
| | - A. M. Traynor
- Mayo Clinic Arizona, Scottsdale, AZ; Indiana University Simon Cancer Center, Indianapolis, IN; Mayo Clinic, Rochester, MN; Institute for Drug Development, Cancer Therapy and Research Center, The University of Texas Health Science Center at San Antonio, San Antonio, TX; Sarah Cannon Research Institute, Nashville, TN; University of Wisconsin Carbone Cancer Center, Madison, WI; Duke University Medical Center, Durham, NC; Pinnacle Oncology Hematology, Scottsdale, AZ; Louisiana State University Health
| | - G. Vlahovic
- Mayo Clinic Arizona, Scottsdale, AZ; Indiana University Simon Cancer Center, Indianapolis, IN; Mayo Clinic, Rochester, MN; Institute for Drug Development, Cancer Therapy and Research Center, The University of Texas Health Science Center at San Antonio, San Antonio, TX; Sarah Cannon Research Institute, Nashville, TN; University of Wisconsin Carbone Cancer Center, Madison, WI; Duke University Medical Center, Durham, NC; Pinnacle Oncology Hematology, Scottsdale, AZ; Louisiana State University Health
| | - D. S. Mendelson
- Mayo Clinic Arizona, Scottsdale, AZ; Indiana University Simon Cancer Center, Indianapolis, IN; Mayo Clinic, Rochester, MN; Institute for Drug Development, Cancer Therapy and Research Center, The University of Texas Health Science Center at San Antonio, San Antonio, TX; Sarah Cannon Research Institute, Nashville, TN; University of Wisconsin Carbone Cancer Center, Madison, WI; Duke University Medical Center, Durham, NC; Pinnacle Oncology Hematology, Scottsdale, AZ; Louisiana State University Health
| | - S. G. Reddy
- Mayo Clinic Arizona, Scottsdale, AZ; Indiana University Simon Cancer Center, Indianapolis, IN; Mayo Clinic, Rochester, MN; Institute for Drug Development, Cancer Therapy and Research Center, The University of Texas Health Science Center at San Antonio, San Antonio, TX; Sarah Cannon Research Institute, Nashville, TN; University of Wisconsin Carbone Cancer Center, Madison, WI; Duke University Medical Center, Durham, NC; Pinnacle Oncology Hematology, Scottsdale, AZ; Louisiana State University Health
| |
Collapse
|
14
|
Kahn DY, Mita AC, George BJ, Sankhala KK, Mahalingam D, Kelly KR, Karnad AB, Sarantopoulos J, Mita MM. Mammalian target of rapamycin (mTOR)-induced pneumonitis: Single-institution experience and treatment. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e13520] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
15
|
Mahalingam D, Beeram M, Rodon J, Sankhala KK, Mita AC, Benjamin D, Michalek J, Tolcher AW, Wright JJ, Sarantopoulos J. Phase II study evaluating the efficacy, safety, and pharmacodynamic correlative study of dual antiangiogenic inhibition using bevacizumab (B) in combination with sorafenib (S) in patients (pts) with advanced malignant melanoma. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e19008] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
16
|
Camidge DR, Ballas MS, Dubey S, Haigentz M, Rosen PJ, Spicer JF, West HJ, Shah GD, Youssoufian H, Mita AC. A phase II, open-label study of ramucirumab (IMC-1121B), an IgG1 fully human monoclonal antibody (MAb) targeting VEGFR-2, in combination with paclitaxel and carboplatin as first-line therapy in patients (pts) with stage IIIb/IV non-small cell lung cancer (NSCLC). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.7588] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
17
|
Schelman WR, Borad MJ, Chiorean EG, Mita AC, Vlahovic G, Mendelson DS, Langmuir VK, Eng C, Kroll S, Bendell JC. Phase I/II study of TH-302 in combination with gemcitabine in patients with solid tumors including advanced pancreatic cancer. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e13519] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
18
|
Mita AC, Heist RS, Aren O, Mainwaring PN, Bazhenova L, Gadgeel SM, Blum RH, Polikoff J, Biswas J, Spear MA. Phase II study of docetaxel with or without plinabulin (NPI-2358) in patients with non-small cell lung cancer (NSCLC). J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.7592] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
19
|
Vlahovic G, Infante JR, Mita AC, Traynor AM, Molina JR, Lacouture ME, Langmuir VK, Eng C, Kroll S, Borad MJ. Phase I/II study of TH-302 in combination with pemetrexed in patients with solid tumors including NSCLC. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.e13535] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
20
|
Rodon Ahnert J, Baselga J, Tawbi HA, Shou Y, Granvil C, Dey J, Mita MM, Thomas AL, Amakye DD, Mita AC. A phase I dose-escalation study of LDE225, a smoothened (Smo) antagonist, in patients with advanced solid tumors. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.2500] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
21
|
Mita AC, Sankhala K, Sarantopoulos J, Carmona J, Okuno S, Goel S, Chugh R, Coffey MC, Mettinger K, Mita MM. A phase II study of intravenous (IV) wild-type reovirus (Reolysin) in the treatment of patients with bone and soft tissue sarcomas metastatic to the lung. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.10524] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
10524 Background: Reolysin is a Dearing strain, naturally occurring, ubiquitous human reovirus. The PKR (double stranded RNA-activated protein kinase) is inhibited and therefore the virus replicates specifically in transformed cells possessing an activated Ras pathway producing lysis. In vitro and in vivo studies with Reolysin in sarcoma cell lines revealed significant antitumor activity. Methods: This phase II open-label, single agent study was designed to characterize the efficacy and safety of Reolysin given IV every 28 days in patients (pts) with bone or soft tissue sarcoma with lung metastasis using a Simon two-stage design. 38 pts were accrued to the first stage. If 1 or more pts experience clinical benefit (prolonged SD > 6 months, partial or complete response) up to 52 pts could be accrued. The agent will be considered active if 3 or more responses or prolonged SD are observed. Results: Since July 2007, 43 pts age 19–76 (median 49) were enrolled (20 female) and received a total of 141 cycles (range 1–18). All pts had performance status 1 (29 pts) or 0 (14 pts). 38 pts received prior chemotherapy, radiotherapy, biological agents or combinations for their metastatic disease, 15 pts received more than 3 chemotherapy regimens. The sarcoma subtypes included: synovial sarcoma (13 pts), osteosarcoma (7 pts), leiomyosarcoma (7 pts), MFH (5 pts), Ewing/PNET (1 pt), chordoma (1 pt), others (9 pts). Side effects were mild to moderate (grade 1–2) and included constitutional symptoms fever, chills, fatigue. Two pts experienced respiratory side effects (cough and dyspnea) and 2 pts had diarrhea. Hematological side effects included grade 2–3 neutropenia (6 pts) and grade 2 thrombocytopenia (2 pts). One patient experienced grade 2 AST elevation. 33 pts are evaluable for response to date: 14 pts (42%) had SD for 2+ months including 5 pts having SD for more than 6 months. Conclusions: Utilization of single agent reovirus for treatment of sarcoma is a novel and unique therapeutic approach to date. Reolysin is well tolerated and shows promise for the treatment of metastatic sarcoma. Primary efficacy goals have been met. Accrual is ongoing to a total of 52 pts. [Table: see text]
Collapse
Affiliation(s)
- A. C. Mita
- Institute for Drug Development, CTRC, UTHSCSA, San Antonio, TX; Mayo Clinic, Rochester, MN; Montefiore Einstein Cancer Center, New York, NY; University of Michigan Health System, Ann Arbor, MI; Oncolytics Biotech Inc., Calgary, AB, Canada
| | - K. Sankhala
- Institute for Drug Development, CTRC, UTHSCSA, San Antonio, TX; Mayo Clinic, Rochester, MN; Montefiore Einstein Cancer Center, New York, NY; University of Michigan Health System, Ann Arbor, MI; Oncolytics Biotech Inc., Calgary, AB, Canada
| | - J. Sarantopoulos
- Institute for Drug Development, CTRC, UTHSCSA, San Antonio, TX; Mayo Clinic, Rochester, MN; Montefiore Einstein Cancer Center, New York, NY; University of Michigan Health System, Ann Arbor, MI; Oncolytics Biotech Inc., Calgary, AB, Canada
| | - J. Carmona
- Institute for Drug Development, CTRC, UTHSCSA, San Antonio, TX; Mayo Clinic, Rochester, MN; Montefiore Einstein Cancer Center, New York, NY; University of Michigan Health System, Ann Arbor, MI; Oncolytics Biotech Inc., Calgary, AB, Canada
| | - S. Okuno
- Institute for Drug Development, CTRC, UTHSCSA, San Antonio, TX; Mayo Clinic, Rochester, MN; Montefiore Einstein Cancer Center, New York, NY; University of Michigan Health System, Ann Arbor, MI; Oncolytics Biotech Inc., Calgary, AB, Canada
| | - S. Goel
- Institute for Drug Development, CTRC, UTHSCSA, San Antonio, TX; Mayo Clinic, Rochester, MN; Montefiore Einstein Cancer Center, New York, NY; University of Michigan Health System, Ann Arbor, MI; Oncolytics Biotech Inc., Calgary, AB, Canada
| | - R. Chugh
- Institute for Drug Development, CTRC, UTHSCSA, San Antonio, TX; Mayo Clinic, Rochester, MN; Montefiore Einstein Cancer Center, New York, NY; University of Michigan Health System, Ann Arbor, MI; Oncolytics Biotech Inc., Calgary, AB, Canada
| | - M. C. Coffey
- Institute for Drug Development, CTRC, UTHSCSA, San Antonio, TX; Mayo Clinic, Rochester, MN; Montefiore Einstein Cancer Center, New York, NY; University of Michigan Health System, Ann Arbor, MI; Oncolytics Biotech Inc., Calgary, AB, Canada
| | - K. Mettinger
- Institute for Drug Development, CTRC, UTHSCSA, San Antonio, TX; Mayo Clinic, Rochester, MN; Montefiore Einstein Cancer Center, New York, NY; University of Michigan Health System, Ann Arbor, MI; Oncolytics Biotech Inc., Calgary, AB, Canada
| | - M. M. Mita
- Institute for Drug Development, CTRC, UTHSCSA, San Antonio, TX; Mayo Clinic, Rochester, MN; Montefiore Einstein Cancer Center, New York, NY; University of Michigan Health System, Ann Arbor, MI; Oncolytics Biotech Inc., Calgary, AB, Canada
| |
Collapse
|
22
|
Sankhala KK, Mita AC, Adinin R, Wood L, Beeram M, Bullock S, Yamagata N, Matsuno K, Fujisawa T, Phan A. A phase I pharmacokinetic (PK) study of MBP-426, a novel liposome encapsulated oxaliplatin. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.2535] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2535 Background: MBP-426 is a novel liposome encapsulated oxaliplatin (L-OHP) formulation bound to human transferrin, developed to improve the safety and efficacy of L -OHP through the prolongation of circulation time and by targeting transferrin receptors on tumor cells. In vitro, MBP-426 is effective against various human cancer cell lines. This study assessed the toxicity and safety of intravenously (IV) administered MBP-426, including defining the maximally tolerated dose (MTD), dose-limiting toxicities (DLTs), and pharmacokinetics (PKs). Methods: Patients (pts) with advanced/ metastatic solid tumors refractory to conventional therapy received MBP-426 as 2–4 hrs IV infusion every 3 weeks in cohorts of 3 to 6 pts. Enrollment required age > 18 yrs, ECOG Performance Status 0–2 and adequate organ functions. Tumor response was assessed by RECIST. Plasma was sampled for PK. Results: 39 pts were dosed, median age 59 (range 27–79), 25 (64%) male. The common tumor types were colorectal 23 (60%), pancreas 3 (8%), and neuroendocrine 3 (8%). Most pts were heavily pretreated with chemotherapy or chemoradiation. 77% pts had received oxaliplatin or cisplatin. Eleven dose levels ranging from 6 to 400 mg/m2 were evaluated. At 400 mg/m2, 2/3 pts had DLT as grade 4 thrombocytopenia and prolonged thrombocytopenia (1 pt each). The recommended phase II dose is 226 mg/m2 where 1/6 pts had grade 4 thrombocytopenia. Grade 3–4 toxicities included fatigue (3 pts), hypercholesterolemia (3 pts), anemia (2 pts) and constipation (1 pt). Common grade 1–2 toxicities were nausea and/or vomiting (59%), fatigue (43%), infusion reaction (15%), thrombocytopenia (15%), anemia (13%) and peripheral neuropathy (13%). 15 pts had stable disease after 2 cycles. 3 pts with colon carcinoma refractory to conventional oxaliplatin had stable disease for 4, 5 and 6 cycles respectively, one of them had 25% decrease in target lesions. PKs of MBP-426 were dose-proportional. Main PK parameters at 226 mg/m2 were AUC 2141+419 μg.hr/ml, and t½ 89+92 hr, comparing favorably with intact L-OHP. Conclusions: MBP-426 has a favorable safety profile with thrombocytopenia as main DLT. The PK target concentration of L-OHP was exceeded at higher doses. Based on PK and toxicity profiles, the recommended dose is 226 mg/m2. [Table: see text]
Collapse
Affiliation(s)
- K. K. Sankhala
- Institute for Drug Development, CTRC at UTHSCSA, San Antonio, TX; University of Texas M. D. Anderson Cancer Center, Houston, TX; Mebiopharm Co., Ltd, Tokyo, Japan
| | - A. C. Mita
- Institute for Drug Development, CTRC at UTHSCSA, San Antonio, TX; University of Texas M. D. Anderson Cancer Center, Houston, TX; Mebiopharm Co., Ltd, Tokyo, Japan
| | - R. Adinin
- Institute for Drug Development, CTRC at UTHSCSA, San Antonio, TX; University of Texas M. D. Anderson Cancer Center, Houston, TX; Mebiopharm Co., Ltd, Tokyo, Japan
| | - L. Wood
- Institute for Drug Development, CTRC at UTHSCSA, San Antonio, TX; University of Texas M. D. Anderson Cancer Center, Houston, TX; Mebiopharm Co., Ltd, Tokyo, Japan
| | - M. Beeram
- Institute for Drug Development, CTRC at UTHSCSA, San Antonio, TX; University of Texas M. D. Anderson Cancer Center, Houston, TX; Mebiopharm Co., Ltd, Tokyo, Japan
| | - S. Bullock
- Institute for Drug Development, CTRC at UTHSCSA, San Antonio, TX; University of Texas M. D. Anderson Cancer Center, Houston, TX; Mebiopharm Co., Ltd, Tokyo, Japan
| | - N. Yamagata
- Institute for Drug Development, CTRC at UTHSCSA, San Antonio, TX; University of Texas M. D. Anderson Cancer Center, Houston, TX; Mebiopharm Co., Ltd, Tokyo, Japan
| | - K. Matsuno
- Institute for Drug Development, CTRC at UTHSCSA, San Antonio, TX; University of Texas M. D. Anderson Cancer Center, Houston, TX; Mebiopharm Co., Ltd, Tokyo, Japan
| | - T. Fujisawa
- Institute for Drug Development, CTRC at UTHSCSA, San Antonio, TX; University of Texas M. D. Anderson Cancer Center, Houston, TX; Mebiopharm Co., Ltd, Tokyo, Japan
| | - A. Phan
- Institute for Drug Development, CTRC at UTHSCSA, San Antonio, TX; University of Texas M. D. Anderson Cancer Center, Houston, TX; Mebiopharm Co., Ltd, Tokyo, Japan
| |
Collapse
|
23
|
Mita AC, Denis LJ, Rowinsky EK, DeBono JS, Goetz AD, Ochoa L, Forouzesh B, Beeram M, Patnaik A, Molpus K, Semiond D, Besenval M, Tolcher AW. Phase I and Pharmacokinetic Study of XRP6258 (RPR 116258A), a Novel Taxane, Administered as a 1-Hour Infusion Every 3 Weeks in Patients with Advanced Solid Tumors. Clin Cancer Res 2009; 15:723-30. [DOI: 10.1158/1078-0432.ccr-08-0596] [Citation(s) in RCA: 274] [Impact Index Per Article: 18.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
24
|
Qin A, Watermill J, Mastico RA, Lutz RJ, O'Keeffe J, Zildjian S, Mita AC, Phan AT, Tolcher AW. The pharmacokinetics and pharmacodynamics of IMGN242 (huC242-DM4) in patients with CanAg-expressing solid tumors. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.3066] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
25
|
Mita AC, Yee LK, Papadopoulos KP, Heath EI, Romero O, Lloyd GK, Cropp G, Spear MA, Mita MM, LoRusso PM. Phase I study of NPI-2358 (a novel vascular disrupting agent) in patients with solid tumors and lymphomas. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.3525] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
26
|
Soefje SA, Sarantopoulos J, Sankhala KK, Mita AC, Mahany Jr. JJ, Carmona T, Coffey M, Gill GM, Mettinger K, Mita MM. A phase II study of intravenous reolysin (wild-type reovirus) in the treatment of patients with bone and soft tissue sarcomas metastatic to the lung. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.10568] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
27
|
Sankhala KK, Takimoto CH, Mita AC, Xiong H, Rodon J, Adinin R, Burns K, Toko T, Arakawa K, Kopetz S. Two phase I, pharmacokinetic (PK) and pharmacodynamic (PD) studies of TAS-109, a novel nucleoside analogue with 14 days and 7 days continuous infusion (CI) schedules. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.2577] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
28
|
Sarantopoulos J, Mita AC, Mulay M, Romero O, Lu J, Capilla F, Chen L, Hwang Y, Friberg G, Rosen LS. A phase IB study of AMG 479, a type 1 insulin-like growth factor receptor (IGF1R) antibody, in combination with panitumumab (P) or gemcitabine (G). J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.3583] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
29
|
Takimoto CH, Fu S, Dhillon N, Mita MM, Mita AC, Cheung W, Xu Y, Ali A, Johri A, Kurzrock R. Evaluation of pharmacokinetics (PK) and pharmacodynamics (PD) of patupilone and warfarin in patients (pts) with advanced solid tumors: An open-label, phase I study. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.2548] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
30
|
Zojwalla NJ, Takimoto CH, Lucarelli AG, Clark R, Mita AC, Mita MM, Romero O, Schuck EL, Krivelevich I, Sweeney CJ. A phase I trial of E7974 administered on days 1, 8, and 15 of a 28-day cycle in patients with solid malignancies. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.2543] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2543 Background: E7974 is a synthetic hemiasterlin analogue exhibiting binding to a and β tubulin. It induces disruption of spindle formation and mitotic arrest characteristic of anti-tubulin cancer drugs. Unlike taxanes and vincas, E7974 is a poor substrate for the PgP drug efflux pump, potentially overcoming this common mechanism of drug resistance. E7974 demonstrates broad anti-tumor activity against a number of human tumor xenografts. Methods: We conducted the initial Phase I trial using an accelerated dose escalation design to determine the maximum tolerated dose (MTD) and pharmacokinetic (PK) profile of E7974 administered IV over 2–5 minutes on Days 1, 8, and 15 of a 28-day cycle. Results: Sixteen patients (7 male, 9 female) with a variety of tumor types and a median age of 54 yrs.(range: 33–78 yrs) were treated at doses of 0.15 mg/m2, 0.21 mg/m2, and 0.29 mg/m2. In the accelerated phase, 0.15 mg/m2 and 0.21 mg/m2 were tolerated. At the 0.29 mg/m2 dose level, one patient experienced grade 4 neutropenia after Day 8. Expansion of the 0.21 mg/m2 dose level resulted in one patient experiencing grade 4 neutropenic fever. Two other patients experienced grades 2 and 3 neutropenia, resulting in delayed dosing beyond Cycle 1. Five additional patients were treated at 0.15 mg/m2; none experienced a DLT or dose delay, thus confirming 0.15 mg/m2 as the MTD. Other observed drug- related toxicities included mild to moderate fatigue, nausea, vomiting, constipation, neuropathy, and myalgias. The PK profile of E7974 can be characterized by moderate to large distribution (Vss = 50 - 133 L), slow clearance (CL = 1.4 - 9 L/hr) and moderate to slow elimination (t1/2 = 6.3 - 31 hr). Approximately 34 - 84% of the administered dose was recovered unchanged in the urine 48 hours post-dose. Stable disease was seen in one patient with colorectal cancer (6 cycles). The MTD cohort has been expanded to a total of 16 evaluable patients for confirmation of tolerability and PK. Conclusions: The recommended Phase 2 dose on Days 1, 8, and 15 of a 28-day schedule is 0.15 mg/m2. Observed toxicities were manageable and reversible. Enrollment is ongoing. [Table: see text]
Collapse
Affiliation(s)
- N. J. Zojwalla
- Eisai Medical Research, Ridgefield Park, NJ; Cancer Therapy and Research Center, San Antonio, TX; Indiana University, Indianapolis, IN; Eisai Research Institute, Andover, MA
| | - C. H. Takimoto
- Eisai Medical Research, Ridgefield Park, NJ; Cancer Therapy and Research Center, San Antonio, TX; Indiana University, Indianapolis, IN; Eisai Research Institute, Andover, MA
| | - A. G. Lucarelli
- Eisai Medical Research, Ridgefield Park, NJ; Cancer Therapy and Research Center, San Antonio, TX; Indiana University, Indianapolis, IN; Eisai Research Institute, Andover, MA
| | - R. Clark
- Eisai Medical Research, Ridgefield Park, NJ; Cancer Therapy and Research Center, San Antonio, TX; Indiana University, Indianapolis, IN; Eisai Research Institute, Andover, MA
| | - A. C. Mita
- Eisai Medical Research, Ridgefield Park, NJ; Cancer Therapy and Research Center, San Antonio, TX; Indiana University, Indianapolis, IN; Eisai Research Institute, Andover, MA
| | - M. M. Mita
- Eisai Medical Research, Ridgefield Park, NJ; Cancer Therapy and Research Center, San Antonio, TX; Indiana University, Indianapolis, IN; Eisai Research Institute, Andover, MA
| | - O. Romero
- Eisai Medical Research, Ridgefield Park, NJ; Cancer Therapy and Research Center, San Antonio, TX; Indiana University, Indianapolis, IN; Eisai Research Institute, Andover, MA
| | - E. L. Schuck
- Eisai Medical Research, Ridgefield Park, NJ; Cancer Therapy and Research Center, San Antonio, TX; Indiana University, Indianapolis, IN; Eisai Research Institute, Andover, MA
| | - I. Krivelevich
- Eisai Medical Research, Ridgefield Park, NJ; Cancer Therapy and Research Center, San Antonio, TX; Indiana University, Indianapolis, IN; Eisai Research Institute, Andover, MA
| | - C. J. Sweeney
- Eisai Medical Research, Ridgefield Park, NJ; Cancer Therapy and Research Center, San Antonio, TX; Indiana University, Indianapolis, IN; Eisai Research Institute, Andover, MA
| |
Collapse
|
31
|
Mita AC, Wang D, Takimoto CH, Malseed E, Nguyen L, Rasmussen E, Storgard C, LoRusso P. AMG 386, a selective angiopoietin 1/2-neutralizing peptibody, in combination with chemotherapy in adult patients with advanced solid tumors. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.14033] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
14033 Introduction: AMG 386 is a selective angiopoietin 1 /2-neutralizing peptibody that inhibits angiogenesis by preventing interaction between angiopoietins and Tie2 receptors. This open-label study evaluated the safety, pharmacokinetics (PK), and antitumor activity of AMG 386 in combination with FOLFOX-4 (F), carboplatin + paclitaxel (CP), or docetaxel (D) in adult patients (pts) with advanced solid tumors. Methods: Three cohorts of 6–9 pts received 1 full cycle of chemotherapy (2 weeks of F or 3 weeks of D 75 mg/m2 or CP). Administration of AMG 386 10 mg/kg IV weekly was started on day 1 of cycle 2 for patients who did not experience a dose-limiting toxicity (DLT) to chemotherapy during cycle 1, and continued until disease progression or intolerance. Safety and tolerability, tumor response (RECIST every 8 weeks), PK profiles of AMG 386 and chemotherapy agents, and formation of antibodies to AMG 386 were assessed. Results: As of October 2, 2006, 16 pts have received AMG 386: 6 pts in the F cohort, 5 in CP, and 5 in D; 7 pts were men, median age 59.5 years (range, 44- 75 years). No AMG 386-related serious AEs or DLTs were reported. AEs related to chemotherapy + AMG 386 in = 2 pts were neutropenia (n = 3), thrombocytopenia (n=2), diarrhea (n=2), and vomiting (n=2). No neutralizing antibodies were observed. F, CP, and D coadministered with AMG 386 did not appear to affect the PK profile of AMG 386, and AMG 386 had no apparent effect on the PK profile of 5 FU, leucovorin, C, P, or D. Tumor response data are available for 6 pts. One pt receiving CP+ AMG 386 for bladder cancer refractory to gemcitabine/cisplatin had a complete response (CR) at week 8, confirmed at week 16. Stable disease in 4 pts and progressive disease in 1 pt were also observed. Conclusions: Weekly administration of AMG 386 in combination with F, CP, or D appears to be safe and well tolerated. A CR in bladder cancer suggests promising antitumor activity of AMG 386 in combination with chemotherapy. Further clinical studies of AMG 386 in combination with chemotherapy and other targeted agents are warranted. [Table: see text]
Collapse
Affiliation(s)
- A. C. Mita
- Institute for Drug Development, San Antonio, TX; Wayne State/Karmanos Cancer Institute, Detroit, MI; Amgen Inc, Thousand Oaks, CA
| | - D. Wang
- Institute for Drug Development, San Antonio, TX; Wayne State/Karmanos Cancer Institute, Detroit, MI; Amgen Inc, Thousand Oaks, CA
| | - C. H. Takimoto
- Institute for Drug Development, San Antonio, TX; Wayne State/Karmanos Cancer Institute, Detroit, MI; Amgen Inc, Thousand Oaks, CA
| | - E. Malseed
- Institute for Drug Development, San Antonio, TX; Wayne State/Karmanos Cancer Institute, Detroit, MI; Amgen Inc, Thousand Oaks, CA
| | - L. Nguyen
- Institute for Drug Development, San Antonio, TX; Wayne State/Karmanos Cancer Institute, Detroit, MI; Amgen Inc, Thousand Oaks, CA
| | - E. Rasmussen
- Institute for Drug Development, San Antonio, TX; Wayne State/Karmanos Cancer Institute, Detroit, MI; Amgen Inc, Thousand Oaks, CA
| | - C. Storgard
- Institute for Drug Development, San Antonio, TX; Wayne State/Karmanos Cancer Institute, Detroit, MI; Amgen Inc, Thousand Oaks, CA
| | - P. LoRusso
- Institute for Drug Development, San Antonio, TX; Wayne State/Karmanos Cancer Institute, Detroit, MI; Amgen Inc, Thousand Oaks, CA
| |
Collapse
|
32
|
Mita MM, Ricart AD, Mita AC, Patnaik A, Sarantopoulos J, Sankhala K, Fram RJ, Qin A, Watermill J, Tolcher AW. A phase I study of a CanAg-targeted immunoconjugate, huC242-DM4, in patients with Can Ag-expressing solid tumors. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.3062] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3062 Background: HuC242-DM4 is a novel, targeted anti-cancer agent in development for the treatment of CanAg-expressing tumors such as carcinomas of the colon and pancreas. The compound is formed by the conjugation of the potent cytotoxic maytansinoid drug, DM4, to the humanized monoclonal antibody, huC242. This agent was highly active across a broad spectrum of CanAg-expressing human tumor xenograft models. Methods: Patients were enrolled with metastatic or inoperable colorectal, pancreatic, and other CanAg-expressing tumors who have failed standard therapy (about 95% of pts. had received = 4 prior chemotherapy regimens). Results: Thirty patients were treated with huC242-DM4, receiving a single intravenous (IV) infusion once every three weeks. Cohorts of 3 patients initially were enrolled on each dose level. Patients have received huC242-DM4 at 18, 36, 60, 90, 126, 168, 223, and 297 mg/m2. To date, dose limiting toxicity (DLT) was experienced by two of six patients treated at the 223 mg/m2 dose level during their second cycle of treatment. The patients experienced decreased visual acuity, corneal deposits and keratitis. Both patients were subsequently treated with lubricating eye drops. At present, these adverse events have markedly improved in one patient, while the other patient has completely returned to baseline. Of 10 patients treated at the168 mg/m2 dose level (including two patients who were dose reduced to 168 mg/m2), seven patients have received at least two cycles of treatment. One patient had grade 3 diarrhea and dehydration during his second cycle at 168 mg/m2. The latter improved with intravenous fluids. Preliminary pharmacokinetic data reveal a half-life of huC242-DM4 of about 5 days in patients with low plasma CanAg levels. In patients with high plasma CanAg levels (>900 units/mL), clearance of huC242-DM4 is increased. There has been no clinically significant myelosuppression and no formation of antibody to humanized antibody (HAHA) or drug (HADA). One patient had a 36% decline in CEA (not associated with tumor shrinkage). Conclusions: HuC242-DM4 was well tolerated at the 168 mg/m2 dose level. The MTD is not yet defined and approaches to prevent /ameliorate ocular toxicity are planned. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- M. M. Mita
- Cancer Therapy and Research Center, San Antonio, TX; ImmunoGen. Inc, Cambridge, MA
| | - A. D. Ricart
- Cancer Therapy and Research Center, San Antonio, TX; ImmunoGen. Inc, Cambridge, MA
| | - A. C. Mita
- Cancer Therapy and Research Center, San Antonio, TX; ImmunoGen. Inc, Cambridge, MA
| | - A. Patnaik
- Cancer Therapy and Research Center, San Antonio, TX; ImmunoGen. Inc, Cambridge, MA
| | - J. Sarantopoulos
- Cancer Therapy and Research Center, San Antonio, TX; ImmunoGen. Inc, Cambridge, MA
| | - K. Sankhala
- Cancer Therapy and Research Center, San Antonio, TX; ImmunoGen. Inc, Cambridge, MA
| | - R. J. Fram
- Cancer Therapy and Research Center, San Antonio, TX; ImmunoGen. Inc, Cambridge, MA
| | - A. Qin
- Cancer Therapy and Research Center, San Antonio, TX; ImmunoGen. Inc, Cambridge, MA
| | - J. Watermill
- Cancer Therapy and Research Center, San Antonio, TX; ImmunoGen. Inc, Cambridge, MA
| | - A. W. Tolcher
- Cancer Therapy and Research Center, San Antonio, TX; ImmunoGen. Inc, Cambridge, MA
| |
Collapse
|
33
|
Takimoto CH, Ricart A, Mita M, Mita AC, Chu Q, Tolcher AW, Sarantopoulos J, Mita A, Rowinsky EK. Phase I evaluation of a 24-h infusion of TAS-106 every 3 weeks (wks) in patients (pts) with solid tumors. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.2513] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2513 Background: The nucleoside 3’-C-ethynylcytidine (TAS-106) is metabolized in cancer cells to ethynylcytidine triphosphate (ECTP), an inhibitor of RNA polymerases I, II, and III. TAS-106 has potent anticancer activity in broad range of human tumor xenografts. In prior clinical studies, bolus intravenous (IV) TAS-106 caused reversible dose-limiting peripheral neuropathy and the recommended phase II dose (RP2D) was 4.21 mg/m2 every 3 wks. Myelosuppression, asthenia, and mild nausea and vomiting were also common. In rats, 24-h TAS-106 infusions are better tolerated with equivalent efficacy. Therefore, a Phase I study of 24-h infusions of TAS-106 was initiated. Methods: Escalating doses TAS-106 infused over 24-h every 3 wks were administered to cancer patients with pharmacokinetic (PK) monitoring during the initial cycle. Toxicity and response were assessed using NCI CTC (v2) grade (gr) and RECIST, respectively. Plasma and urine TAS-106 concentrations were monitored using LC/MS/MS methods. Results: Overall, 33 pts were treated at the following dose levels: 2.82 (4 pts), 3.5 (5 pts), 4.38 (6 pts), 5.48 (4 pts) 6.85 (6 pts) and 8.56 mg/m2 (8 pts). At 8.56 mg/m2, 2 of 5 pts experienced neutropenic DLTs (febrile neutropenia and gr 4 neutropenia lasting greater than or equal to 3 days) No neuropathy DLTs were observed. At 6.85 mg/m2, gr 3 peripheral neuropathy in cycle 1 was observed in 1 patient, but no other DLTs occurred in 5 patients. Other common drug related toxicities occurring in any cycle included gr 1–2 fatigue (13 pts), gr 3–4 neutropenia (10 pts), gr 1 hand/foot syndrome (9 pts), gr 2–3 anemia (9 pts) gr 1 rash/skin exfoliation (10 pts), and peripheral neuropathy gr 1–2 (5 pts). No objective responses were seen; although 3 pts with parotid, adenoid cystic, and breast cancers demonstrated stable disease for 5, 6, and 7 months, respectively. Plasma concentrations increased with increasing dose, and at 6.85 mg/m2, the Cmax was 77.4±7.3 ng/mL, AUC 1,892±54 ng·h/mL, CL 102±13 mL/h/kg, VDss 1.37±.05 L/kg, and t1/2 was 9.85±1.47 h. Over 48 h, 62.1% of the administered dose of TAS-106 was excreted into the urine. Conclusions: Compared with bolus dosing, 24-h infusions of TAS-106 are better tolerated with less peripheral neuropathy. The RP2D for TAS-106 infused over 24-h every 3 wks is 6.85 mg/m2. [Table: see text]
Collapse
Affiliation(s)
- C. H. Takimoto
- Institute for Drug Development, San Antonio, TX; Taiho Pharmaceutical Co.,Ltd., Tokyo, Japan
| | - A. Ricart
- Institute for Drug Development, San Antonio, TX; Taiho Pharmaceutical Co.,Ltd., Tokyo, Japan
| | - M. Mita
- Institute for Drug Development, San Antonio, TX; Taiho Pharmaceutical Co.,Ltd., Tokyo, Japan
| | - A. C. Mita
- Institute for Drug Development, San Antonio, TX; Taiho Pharmaceutical Co.,Ltd., Tokyo, Japan
| | - Q. Chu
- Institute for Drug Development, San Antonio, TX; Taiho Pharmaceutical Co.,Ltd., Tokyo, Japan
| | - A. W. Tolcher
- Institute for Drug Development, San Antonio, TX; Taiho Pharmaceutical Co.,Ltd., Tokyo, Japan
| | - J. Sarantopoulos
- Institute for Drug Development, San Antonio, TX; Taiho Pharmaceutical Co.,Ltd., Tokyo, Japan
| | - A. Mita
- Institute for Drug Development, San Antonio, TX; Taiho Pharmaceutical Co.,Ltd., Tokyo, Japan
| | - E. K. Rowinsky
- Institute for Drug Development, San Antonio, TX; Taiho Pharmaceutical Co.,Ltd., Tokyo, Japan
| |
Collapse
|
34
|
Mita MM, Mita AC, Ricart A, Rodon J, Till E, Okereke C, Desai P, Zang E, Rowinsky EK, Takimoto C. Phase I study of an anti-angiogenic agent with a novel mechanism of action E7820: Safety, pharmacokinetics (PK) and pharmacodynamic (PD) studies in patients (pts) with solid tumors. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.3048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
3048 Background: E7820 is a first-in-class oral antiangiogenic sulfonamide that inhibits alpha-2 integrin expression, endothelial cell proliferation and is active against human breast and pancreatic cancer xenografts. Methods: The objectives of the study were to evaluate the safety, tolerability, to determine the maximum tolerated dose (MTD) to characterize the PK behavior, to assess PD markers and to explore the antitumor activity. Results: Thirty pts (18 male/12 female; age range 40–83) received E7820 at doses ranging from 10 to 200 mg daily continuously, in a 28 day cycle. A total of 93 cycles were administered (range 1–15); 4 pts underwent intrapatient dose escalation. Dose-limiting toxicities (DLT) at 100 mg/day included grade (gr) 3 elevated liver enzymes and gr 3 hemoptysis. At the 200 mg dose level, 2 pts experienced hematological toxicity, including gr 4 thrombocytopenia and neutropenia. One of these patients with cervical cancer and a vaginal fistula had gr 4 thrombocytopenia, neutropenia and gr 3 anemia with a fatal bleed from her pelvic tumor. Other gr 3/4 adverse events included: nausea, vomiting, fatigue, hypoxia, chest pain, abdominal pain, ileus, anemia, neutropenia, hypoalbuminemia, elevated transaminases and alkaline phosphatases. Disease stabilization beyond cycle 4 was observed in 6 pts, with 3 lasting for 6+ months. Tmax ranged from 1.3–5.3 hr and the t1/2 is 5.7 to 11.9 hr. Cmax and AUC increased dose proportionaly up to 70 mg, however accumulation was seen at 200 mg. At higher doses (70–200 mg) plasma concentrations exceed levels active in preclinical models in vivo. Preliminary analysis of alpha-2 integrin expression showed marked (∼50%) and sustained decreases beyond day 28 in 3 of 4 pts at 200 mg, while moderate (<30%) and less consistent decreases were observed in 2/3 and 3/6 pts at 70 mg and 100 mg dose levels, respectively. No changes in integrin levels were observed at E7820 doses < 40 mg. Conclusions: Up to 100 mg/day E7820 has a good safety profile in pts with solid malignancies. MTD was established at 100 mg/day. Patient treatment and PD analyses are ongoing. [Table: see text]
Collapse
Affiliation(s)
- M. M. Mita
- Cancer Therapy and Research Center, San Antonio, TX; Eisai Medical Research, Inc., Ridgefield Park, NJ
| | - A. C. Mita
- Cancer Therapy and Research Center, San Antonio, TX; Eisai Medical Research, Inc., Ridgefield Park, NJ
| | - A. Ricart
- Cancer Therapy and Research Center, San Antonio, TX; Eisai Medical Research, Inc., Ridgefield Park, NJ
| | - J. Rodon
- Cancer Therapy and Research Center, San Antonio, TX; Eisai Medical Research, Inc., Ridgefield Park, NJ
| | - E. Till
- Cancer Therapy and Research Center, San Antonio, TX; Eisai Medical Research, Inc., Ridgefield Park, NJ
| | - C. Okereke
- Cancer Therapy and Research Center, San Antonio, TX; Eisai Medical Research, Inc., Ridgefield Park, NJ
| | - P. Desai
- Cancer Therapy and Research Center, San Antonio, TX; Eisai Medical Research, Inc., Ridgefield Park, NJ
| | - E. Zang
- Cancer Therapy and Research Center, San Antonio, TX; Eisai Medical Research, Inc., Ridgefield Park, NJ
| | - E. K. Rowinsky
- Cancer Therapy and Research Center, San Antonio, TX; Eisai Medical Research, Inc., Ridgefield Park, NJ
| | - C. Takimoto
- Cancer Therapy and Research Center, San Antonio, TX; Eisai Medical Research, Inc., Ridgefield Park, NJ
| |
Collapse
|
35
|
Mita MM, Mita AC, Goldston M, Chu QS, Tolcher AW, Ricart A, Desai P, Okereke CS, Rowinsky EK, Takimoto C. Pharmacokinetics (PK) and pharmacodynamics (PD) of E7820-an oral sulfonamide with novel, alpha-2 integrin mediated antiangiogenic properties: Results of a phase I study. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.3082] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. M. Mita
- Cancer Therapy & Research Ctr, San Antonio, TX; Eisai Global Clin, Ridgefield, NJ; Eisai Global Clin, Ridgefield Park, NJ
| | - A. C. Mita
- Cancer Therapy & Research Ctr, San Antonio, TX; Eisai Global Clin, Ridgefield, NJ; Eisai Global Clin, Ridgefield Park, NJ
| | - M. Goldston
- Cancer Therapy & Research Ctr, San Antonio, TX; Eisai Global Clin, Ridgefield, NJ; Eisai Global Clin, Ridgefield Park, NJ
| | - Q. S. Chu
- Cancer Therapy & Research Ctr, San Antonio, TX; Eisai Global Clin, Ridgefield, NJ; Eisai Global Clin, Ridgefield Park, NJ
| | - A. W. Tolcher
- Cancer Therapy & Research Ctr, San Antonio, TX; Eisai Global Clin, Ridgefield, NJ; Eisai Global Clin, Ridgefield Park, NJ
| | - A. Ricart
- Cancer Therapy & Research Ctr, San Antonio, TX; Eisai Global Clin, Ridgefield, NJ; Eisai Global Clin, Ridgefield Park, NJ
| | - P. Desai
- Cancer Therapy & Research Ctr, San Antonio, TX; Eisai Global Clin, Ridgefield, NJ; Eisai Global Clin, Ridgefield Park, NJ
| | - C. S. Okereke
- Cancer Therapy & Research Ctr, San Antonio, TX; Eisai Global Clin, Ridgefield, NJ; Eisai Global Clin, Ridgefield Park, NJ
| | - E. K. Rowinsky
- Cancer Therapy & Research Ctr, San Antonio, TX; Eisai Global Clin, Ridgefield, NJ; Eisai Global Clin, Ridgefield Park, NJ
| | - C. Takimoto
- Cancer Therapy & Research Ctr, San Antonio, TX; Eisai Global Clin, Ridgefield, NJ; Eisai Global Clin, Ridgefield Park, NJ
| |
Collapse
|
36
|
Mays TA, Mita AC, Takimoto C, Petro D, Egorin MJ, Patnaik A, Papodopolous K, Rowinsky E, Goldston M, Tolcher A. Bcl-2 biomodulation with oblimersen sodium in combination with FOLFOX4 chemotherapy: A phase I study in metastatic colon carcinoma. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.3158] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- T. A. Mays
- Cancer Thrpy Rsrch, San Antonio, TX; Univ of Pittsburgh Cancer Institute, Pittsburgh, PA; Univ of Texas Health Sciences Ctr, San Antonio, TX
| | - A. C. Mita
- Cancer Thrpy Rsrch, San Antonio, TX; Univ of Pittsburgh Cancer Institute, Pittsburgh, PA; Univ of Texas Health Sciences Ctr, San Antonio, TX
| | - C. Takimoto
- Cancer Thrpy Rsrch, San Antonio, TX; Univ of Pittsburgh Cancer Institute, Pittsburgh, PA; Univ of Texas Health Sciences Ctr, San Antonio, TX
| | - D. Petro
- Cancer Thrpy Rsrch, San Antonio, TX; Univ of Pittsburgh Cancer Institute, Pittsburgh, PA; Univ of Texas Health Sciences Ctr, San Antonio, TX
| | - M. J. Egorin
- Cancer Thrpy Rsrch, San Antonio, TX; Univ of Pittsburgh Cancer Institute, Pittsburgh, PA; Univ of Texas Health Sciences Ctr, San Antonio, TX
| | - A. Patnaik
- Cancer Thrpy Rsrch, San Antonio, TX; Univ of Pittsburgh Cancer Institute, Pittsburgh, PA; Univ of Texas Health Sciences Ctr, San Antonio, TX
| | - K. Papodopolous
- Cancer Thrpy Rsrch, San Antonio, TX; Univ of Pittsburgh Cancer Institute, Pittsburgh, PA; Univ of Texas Health Sciences Ctr, San Antonio, TX
| | - E. Rowinsky
- Cancer Thrpy Rsrch, San Antonio, TX; Univ of Pittsburgh Cancer Institute, Pittsburgh, PA; Univ of Texas Health Sciences Ctr, San Antonio, TX
| | - M. Goldston
- Cancer Thrpy Rsrch, San Antonio, TX; Univ of Pittsburgh Cancer Institute, Pittsburgh, PA; Univ of Texas Health Sciences Ctr, San Antonio, TX
| | - A. Tolcher
- Cancer Thrpy Rsrch, San Antonio, TX; Univ of Pittsburgh Cancer Institute, Pittsburgh, PA; Univ of Texas Health Sciences Ctr, San Antonio, TX
| |
Collapse
|
37
|
Patnaik A, Mita AC, Izbicka E, Carrizales G, Howes A, Troenaru M, Tolcher AW, Zhang S, Berg K, Rowinsky EK. A phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study of the farnesyl transferase inhibitor (FTI) R115777 in combination with weekly paclitaxel in patients (pts) with advanced solid cancers. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.3136] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- A. Patnaik
- Cancer Therapy & Research Center, San Antonio, TX; Johnson & Johnson Pharmaceutical Research & Dev, Raritan, NJ
| | - A. C. Mita
- Cancer Therapy & Research Center, San Antonio, TX; Johnson & Johnson Pharmaceutical Research & Dev, Raritan, NJ
| | - E. Izbicka
- Cancer Therapy & Research Center, San Antonio, TX; Johnson & Johnson Pharmaceutical Research & Dev, Raritan, NJ
| | - G. Carrizales
- Cancer Therapy & Research Center, San Antonio, TX; Johnson & Johnson Pharmaceutical Research & Dev, Raritan, NJ
| | - A. Howes
- Cancer Therapy & Research Center, San Antonio, TX; Johnson & Johnson Pharmaceutical Research & Dev, Raritan, NJ
| | - M. Troenaru
- Cancer Therapy & Research Center, San Antonio, TX; Johnson & Johnson Pharmaceutical Research & Dev, Raritan, NJ
| | - A. W. Tolcher
- Cancer Therapy & Research Center, San Antonio, TX; Johnson & Johnson Pharmaceutical Research & Dev, Raritan, NJ
| | - S. Zhang
- Cancer Therapy & Research Center, San Antonio, TX; Johnson & Johnson Pharmaceutical Research & Dev, Raritan, NJ
| | - K. Berg
- Cancer Therapy & Research Center, San Antonio, TX; Johnson & Johnson Pharmaceutical Research & Dev, Raritan, NJ
| | - E. K. Rowinsky
- Cancer Therapy & Research Center, San Antonio, TX; Johnson & Johnson Pharmaceutical Research & Dev, Raritan, NJ
| |
Collapse
|
38
|
Mita MM, Rowinsky EK, Goldston ML, Mita AC, Chu Q, Syed S, Knowles HL, Rivera VM, Bedrosian CL, Tolcher AW. Phase I, pharmacokinetic (PK), and pharmacodynamic (PD) study of AP23573, an mTOR Inhibitor, administered IV daily X 5 every other week in patients (pts) with refractory or advanced malignancies. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.3076] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- M. M. Mita
- Cancer Therapy & Research Center, San Antonio, TX; ARIAD Pharmaceuticals, Inc, Cambridge, MA; ARIAD Pharmaceuticals, Cambridge, MA
| | - E. K. Rowinsky
- Cancer Therapy & Research Center, San Antonio, TX; ARIAD Pharmaceuticals, Inc, Cambridge, MA; ARIAD Pharmaceuticals, Cambridge, MA
| | - M. L. Goldston
- Cancer Therapy & Research Center, San Antonio, TX; ARIAD Pharmaceuticals, Inc, Cambridge, MA; ARIAD Pharmaceuticals, Cambridge, MA
| | - A. C. Mita
- Cancer Therapy & Research Center, San Antonio, TX; ARIAD Pharmaceuticals, Inc, Cambridge, MA; ARIAD Pharmaceuticals, Cambridge, MA
| | - Q. Chu
- Cancer Therapy & Research Center, San Antonio, TX; ARIAD Pharmaceuticals, Inc, Cambridge, MA; ARIAD Pharmaceuticals, Cambridge, MA
| | - S. Syed
- Cancer Therapy & Research Center, San Antonio, TX; ARIAD Pharmaceuticals, Inc, Cambridge, MA; ARIAD Pharmaceuticals, Cambridge, MA
| | - H. L. Knowles
- Cancer Therapy & Research Center, San Antonio, TX; ARIAD Pharmaceuticals, Inc, Cambridge, MA; ARIAD Pharmaceuticals, Cambridge, MA
| | - V. M. Rivera
- Cancer Therapy & Research Center, San Antonio, TX; ARIAD Pharmaceuticals, Inc, Cambridge, MA; ARIAD Pharmaceuticals, Cambridge, MA
| | - C. L. Bedrosian
- Cancer Therapy & Research Center, San Antonio, TX; ARIAD Pharmaceuticals, Inc, Cambridge, MA; ARIAD Pharmaceuticals, Cambridge, MA
| | - A. W. Tolcher
- Cancer Therapy & Research Center, San Antonio, TX; ARIAD Pharmaceuticals, Inc, Cambridge, MA; ARIAD Pharmaceuticals, Cambridge, MA
| |
Collapse
|